Christopher Parker1, Steven E Finkelstein2, Jeff M Michalski3, Joe M O'Sullivan4, Øyvind Bruland5, Nicholas J Vogelzang6, Robert E Coleman7, Sten Nilsson8, Oliver Sartor9, Rui Li10, Monica A Seger10, David Bottomley11. 1. Royal Marsden Hospital, Sutton, London, UK. Electronic address: chris.parker@rmh.nhs.uk. 2. Cancer Treatment Centers of America, Tulsa, OK, USA. 3. Washington University School of Medicine, St Louis, MO, USA. 4. Center for Cancer Research and Cell Biology, Queen's University, Belfast, UK. 5. Norwegian Radium Hospital, Oslo, Norway. 6. Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA. 7. University of Sheffield, Sheffield, South Yorkshire, UK. 8. Karolinska University Hospital, Stockholm, Sweden. 9. Tulane Cancer Center, New Orleans, LA, USA. 10. Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA. 11. St. James University Hospital, Leeds, Yorkshire, UK.
Abstract
BACKGROUND: The phase 3 ALSYMPCA trial enrolled metastatic castration-resistant prostate cancer patients with or without baseline opioid use. OBJECTIVE: To assess the efficacy and safety of radium-223 dichloride (radium-223) versus placebo in ALSYMPCA patients by baseline opioid use. DESIGN, SETTING, AND PARTICIPANTS: Nine hundred and twenty one patients enrolled at 136 centers globally. INTERVENTION: Radium-223 (50 kBq/kg, intravenous injection) every 4 wk for six cycles or matching placebo, each plus best standard of care. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary endpoint (overall survival [OS]), main secondary efficacy endpoints, and safety were evaluated by baseline opioid use. Additional analyses included time to first opioid use, time to first external beam radiation therapy for bone pain, and safety of concomitant external beam radiation therapy. RESULTS AND LIMITATIONS: At baseline, 408 (44%) patients had no pain and no analgesic use or mild pain withnonopioid therapy (World Health Organization ladder pain score 0-1 [nonopioid subgroup]), and 513 (56%) had moderate pain with occasional opioids or severe pain with regular daily opioids (World Health Organization ladder pain score 2-3 [opioid subgroup]). Radium-223 significantly prolonged OS versus placebo in nonopioid (hazard ratio [HR]=0.70; 95% confidence interval [CI]: 0.52-0.93; p=0.013) and opioid (HR=0.68; 95% CI: 0.54-0.86; p=0.001) subgroups, and significantly reduced risk of symptomatic skeletal events versus placebo, regardless of baseline opioid use (nonopioid subgroup: HR=0.56, 95% CI: 0.39-0.82, p=0.002; opioid subgroup: HR=0.72, 95% CI: 0.53-0.98, p=0.038). Time to first opioid use for bone pain was significantly delayed with radium-223 versus placebo (HR=0.62, 95% CI: 0.46-0.85, p=0.002). Adverse event incidences were similar between opioid subgroups. CONCLUSIONS:Radium-223 versus placebo significantly prolonged OS and reduced symptomatic skeletal event risk with a favorable safety profile in castration-resistant prostate cancer patients with symptomatic bone metastases, regardless of baseline opioid use. PATIENT SUMMARY: In this ALSYMPCA opioid subgroup analysis, baseline symptom levels did not appear to impact radium-223 dichloride efficacy or safety.
RCT Entities:
BACKGROUND: The phase 3 ALSYMPCA trial enrolled metastatic castration-resistant prostate cancerpatients with or without baseline opioid use. OBJECTIVE: To assess the efficacy and safety of radium-223 dichloride (radium-223) versus placebo in ALSYMPCA patients by baseline opioid use. DESIGN, SETTING, AND PARTICIPANTS: Nine hundred and twenty one patients enrolled at 136 centers globally. INTERVENTION: Radium-223 (50 kBq/kg, intravenous injection) every 4 wk for six cycles or matching placebo, each plus best standard of care. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary endpoint (overall survival [OS]), main secondary efficacy endpoints, and safety were evaluated by baseline opioid use. Additional analyses included time to first opioid use, time to first external beam radiation therapy for bone pain, and safety of concomitant external beam radiation therapy. RESULTS AND LIMITATIONS: At baseline, 408 (44%) patients had no pain and no analgesic use or mild pain with nonopioid therapy (World Health Organization ladder pain score 0-1 [nonopioid subgroup]), and 513 (56%) had moderate pain with occasional opioids or severe pain with regular daily opioids (World Health Organization ladder pain score 2-3 [opioid subgroup]). Radium-223 significantly prolonged OS versus placebo in nonopioid (hazard ratio [HR]=0.70; 95% confidence interval [CI]: 0.52-0.93; p=0.013) and opioid (HR=0.68; 95% CI: 0.54-0.86; p=0.001) subgroups, and significantly reduced risk of symptomatic skeletal events versus placebo, regardless of baseline opioid use (nonopioid subgroup: HR=0.56, 95% CI: 0.39-0.82, p=0.002; opioid subgroup: HR=0.72, 95% CI: 0.53-0.98, p=0.038). Time to first opioid use for bone pain was significantly delayed with radium-223 versus placebo (HR=0.62, 95% CI: 0.46-0.85, p=0.002). Adverse event incidences were similar between opioid subgroups. CONCLUSIONS:Radium-223 versus placebo significantly prolonged OS and reduced symptomatic skeletal event risk with a favorable safety profile in castration-resistant prostate cancerpatients with symptomatic bone metastases, regardless of baseline opioid use. PATIENT SUMMARY: In this ALSYMPCA opioid subgroup analysis, baseline symptom levels did not appear to impact radium-223 dichloride efficacy or safety.
Authors: Mari I Suominen; Katja M Fagerlund; Jukka P Rissanen; Yvonne M Konkol; Jukka P Morko; ZhiQi Peng; Esa J Alhoniemi; Salla K Laine; Eva Corey; Dominik Mumberg; Karl Ziegelbauer; Sanna-Maria Käkönen; Jussi M Halleen; Robert L Vessella; Arne Scholz Journal: Clin Cancer Res Date: 2017-03-31 Impact factor: 12.531
Authors: Maarten J van der Doelen; Irma M Oving; Dirk N J Wyndaele; Jean-Paul van Basten; Frederiek Terheggen; Addy C M van de Luijtgaarden; Wim J G Oyen; W Dick van Schelven; Franchette van den Berkmortel; Niven Mehra; Marcel J R Janssen; Judith B Prins; Winald R Gerritsen; José A E Custers; Inge M van Oort Journal: Prostate Cancer Prostatic Dis Date: 2022-07-08 Impact factor: 5.554
Authors: Diane E Milenic; Kwamena E Baidoo; Young-Seung Kim; Rachel Barkley; Martin W Brechbiel Journal: Dalton Trans Date: 2017-10-31 Impact factor: 4.390
Authors: Juan Pablo Sade; Carlos Alberto Vargas Báez; Martin Greco; Carlos Humberto Martínez; Miguel Ángel Álvarez Avitia; Carlos Palazzo; Narciso Hernández Toriz; Patricia Isabel Bernal Trujillo; Diogo Assed Bastos; Fabio Augusto Schutz; Santiago Bella; Lucas Nogueira; Neal D Shore Journal: Med Oncol Date: 2018-03-19 Impact factor: 3.064